Active	Status	Sponsor type	Region	Phase	Filter
1 Active 5 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ISIS-EIF4ERx / Ionis
2008-001535-35: A Phase 1b/2 Study of Gemcitabine-Cisplatin, With or Without LY2275796 Sodium, in Patients with Advanced Stage IIIB or IV Non-Small Cell Lung Cancer	Ongoing	1/2	15	Europe	LY2275796 Sodium, Gemzar, LY2275796, Gemzar, Cisplatine Merck, Gemzar, Cisplatine Merck	Eli Lilly and Company	Non Small Cell Lung Cancer ( NSCLC)

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ISIS-EIF4ERx / Ionis
2008-001535-35: A Phase 1b/2 Study of Gemcitabine-Cisplatin, With or Without LY2275796 Sodium, in Patients with Advanced Stage IIIB or IV Non-Small Cell Lung Cancer	Ongoing	1/2	15	Europe	LY2275796 Sodium, Gemzar, LY2275796, Gemzar, Cisplatine Merck, Gemzar, Cisplatine Merck	Eli Lilly and Company	Non Small Cell Lung Cancer ( NSCLC)